key: cord-0728699-u486gjrm
authors: Suvvari, Tarun K.; Rajesh, Eshwar; D Silva, Reewen G.; Corriero, Anna C.; Kutikuppala, L. V. Simhachalam
title: SARS‐CoV‐2 vaccine‐induced prothrombotic immune thrombocytopenia: Promoting awareness to improve patient‐doctor trust
date: 2021-07-11
journal: J Med Virol
DOI: 10.1002/jmv.27176
sha: b6eedd3f1fec18b4f27ec27e063528148cbd4ffe
doc_id: 728699
cord_uid: u486gjrm

nan

Vaccine-induced prothrombotic immune thrombocytopenia (VI-PIT) also referred to as thrombosis with thrombocytopenia syndrome is characterised by mild to severe thrombocytopenia, venous or arterial thrombosis at sites such as cerebral venous thrombosis/ splanchnic thrombosis and positive PF-4 heparin enzyme-linked immunosorbent assay (ELISA). 1 It has been observed that this phenomenon has an underlying immunological mechanism similar to that of heparin-induced thrombocytopenia (HIT); however, it was reported that this is not triggered by heparin, hence it imitates spontaneous autoimmune HIT (aHIT) with the identification of antibodies to platelet factor-4 (PF4). 1, 2 HIT is a prothrombotic adverse reaction, caused by the brief production of IgG class of platelet-activating antibodies which recognise the PF4 which are cationic and bind to heparin which is polyanionic. 2 In aHIT there is uniformly positive PF4-heparin ELISAs, with the circulating PF4-reactive antibodies which activate platelets in the absence of heparin. 1 The binding of aHIT antibodies to PF4 brings in heparin-dependent antibodies to form large immune complexes thus flaring up the reaction. 2 Patients so far have presented with symptoms of headaches followed by rapid neurological deterioration after vaccination. 3 This reaction is a rarely seen and highly unique event which has been reported in patients after vaccination. 4 Other rarely recorded autoimmune diseases include Guillian Barre syndrome, which was seen in influenza vaccination. 4 The constellation of signs, symptoms, and reports seen in the patients have not been previously described in the medical literature as a possible postvaccination reaction. Hence an association between the clinical syndrome and vaccination is suspected. 4 There have been isolated case reports in various regions of the world involving signs of thrombotic thrombocytopenia following COVID-19 vaccination. In Table 1 , we outlined the reported and published COVID-19 VIPIT 5-9 till date providing a detailed description of the events. The incidence remains largely unknown, however it appears that an incidence of 1 in 125,000 was seen after vaccination with the AstraZeneca vaccine (ChA-dOx1 nCoV-19). 10 In conclusion, it is important to monitor patients presenting with the above described symptoms in all cases but particular attention is required when patients report a history of recent COVID-19 vaccination. Patients that present with similar symptoms and normal full blood count might be at the early stages of the side effect, therefore they should also be continuously monitored to avoid fatality. Awareness of the side effects and the protocols established to provide the best possible care is fundamental, to avoid fatalities and to reassure patients that they are always at the centre of the work of healthcare professionals during this crisis. 

COVID-19 resources-thrombosis with thrombocytopenia syndrome

Autoimmune heparin-induced thrombocytopenia

Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination-a report of two UK cases

Guillain-Barré syndrome following influenza vaccination

Immune thrombocytopenia in a 22-yearold post COVID-19 vaccine

Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Familial thrombocytopenia flare-up following the first dose of

Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) following AstraZeneca COVID-19 vaccination

CDC. Recommends use of Johnson & Johnson's Janssen COVID-19 vaccine resume

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia